```html

Exudative Age‑Related Macular Degeneration (Wet AMD)

Overview

Age‑related macular degeneration (AMD) is a progressive eye disease that damages the macula – the central portion of the retina responsible for sharp, straight‑ahead vision. There are two major forms:

• Dry (atrophic) AMD – accounts for ~85‑90 % of cases.
• Exudative (wet or neovascular) AMD – only 10‑15 % of AMD patients, but responsible for > 80 % of severe vision loss.

Exudative AMD occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, leading to rapid deterioration of central vision.

Who it affects: Primarily people ≥ 60 years old. In the United States, about 1.5 million adults have wet AMD; worldwide prevalence is estimated at 8‑10 million people (World Health Organization, 2022).

Symptoms

Symptoms can appear suddenly and progress quickly. If you notice any of the following, schedule an eye exam promptly.

• Blurry or distorted central vision – straight lines may appear wavy (metamorphopsia).
• Dark or empty spot in the center of your visual field – often described as a “black spot” or “hole.”
• Decreased ability to see colors accurately – colors may look faded.
• Reduced contrast sensitivity – difficulty discerning objects against a similarly‑colored background.
• Difficulty reading or recognizing faces – especially when holding reading material at a normal distance.
• Increased need for brighter light – tasks that were previously easy become strenuous.
• Pain or pressure in the eye – uncommon but may signal an acute bleed.
• Sudden vision loss – a rapid decline over days to weeks is a red flag.

Causes and Risk Factors

Primary Pathophysiology

Wet AMD results from angiogenesis (growth of new blood vessels) driven by an imbalance of growth factors, especially vascular endothelial growth factor (VEGF). These fragile vessels rupture, leaking fluid, lipids, and blood into the sub‑retinal space, causing scarring and loss of photoreceptors.

Risk Factors

• Age – risk rises sharply after 60; > 85 years carries the highest risk.
• Genetics – variants in CFH, ARMS2/HTRA1, and other complement pathway genes increase susceptibility (NIH, 2021).
• Smoking – current smokers have a 2–3‑fold higher risk; risk persists for years after quitting.
• Race/Ethnicity – higher prevalence in Caucasians; lower in African‑American and Asian populations.
• Cardiovascular disease – hypertension, hyperlipidemia, and atherosclerosis are linked to AMD.
• Obesity – BMI ≥ 30 kg/m² associated with 30‑40 % increased risk.
• Family history – having a first‑degree relative with AMD roughly doubles your risk.
• Diet low in antioxidants & lutein/zeaxanthin – inadequate intake of leafy greens may predispose to retinal damage.
• Light exposure – chronic UV or blue‑light exposure may contribute, though evidence is mixed.

Diagnosis

Early detection is essential because timely treatment can preserve vision.

Clinical Examination

• Visual acuity test – measures central vision using a Snellen chart.
• Amsler grid – patients look at a grid and report any distortions; useful for self‑monitoring.
• Fundoscopic exam – ophthalmologist uses an ophthalmoscope to look for drusen, pigment changes, and signs of neovascularization.

Imaging Modalities

• Optical Coherence Tomography (OCT) – non‑invasive cross‑sectional imaging that shows fluid accumulation, sub‑retinal hemorrhage, and retinal thickening. OCT is the cornerstone for diagnosing wet AMD.
• Fluorescein Angiography (FA) – dye injected intravenously highlights leaking vessels; helps map the extent of neovascular membranes.
• Indocyanine Green Angiography (ICGA) – better visualizes deeper choroidal vessels, useful for certain sub‑types.
• Fundus Autofluorescence (FAF) – evaluates retinal pigment epithelium health.

Laboratory Tests

Not routinely required for diagnosis, but blood work (lipid panel, HbA1c) may be ordered to address modifiable risk factors.

Treatment Options

Unlike dry AMD, wet AMD has effective, evidence‑based therapies that can halt or even improve vision.

Anti‑VEGF Intravitreal Injections

First‑line treatment. Medications bind VEGF, preventing new vessel growth and reducing leakage.

• Aflibercept (Eylea) – administered every 4–8 weeks after loading doses.
• Ranibizumab (Lucentis) – approved for monthly or “treat‑and‑extend” regimens.
• Bevacizumab (Avastin) – off‑label; less costly, similar efficacy.
• Faricimab (Vabysmo) – newer agent targeting both VEGF and Ang‑2; dosing may extend up to 16 weeks.

Clinical trials show that 30‑40 % of patients gain ≥ 15 letters (≈ 3 lines) of visual acuity after 12 months of therapy (Mayo Clinic, 2023).

Photodynamic Therapy (PDT)

Used less frequently, PDT involves verteporfin infusion followed by laser activation to selectively close abnormal vessels. Often combined with anti‑VEGF agents for polypoidal choroidal vasculopathy.

Laser Photocoagulation

Direct laser destroys leaking vessels, but risks collateral retinal damage; now largely supplanted by anti‑VEGF therapy.

Surgical Options

• Vitrectomy – removal of vitreous hemorrhage or sub‑retinal blood when medical therapy is insufficient.
• Sub‑retinal surgery – experimental; not widely available.

Lifestyle & Adjunctive Measures

• Smoking cessation – reduces progression risk.
• Diet rich in leafy greens, fish (omega‑3), and antioxidants – supported by AREDS2 trial to slow AMD progression.
• Blood pressure & cholesterol control – manage via diet, exercise, and medications as directed by your primary care physician.
• Protective eyewear – UV‑blocking sunglasses may limit further retinal stress.

Living with Exudative Age‑Related Macular Degeneration

Vision‑Maximizing Strategies

• Amsler grid monitoring – check daily; report any new distortion immediately.
• High‑contrast, large‑print reading material – use magnifiers, electronic readers, or screen‑reading software.
• Adaptive lighting – bright, glare‑free task lighting reduces strain.
• Low‑vision rehabilitation – occupational therapists can train on eccentric viewing (using peripheral retina) and provide assistive devices.

Emotional & Social Support

Vision loss can affect mood and independence. Consider:

• Joining AMD support groups (American Macular Degeneration Foundation, local community groups).
• Counseling or psychotherapy for anxiety/depression.
• Education of family members on how to assist with daily activities safely.

Follow‑up Schedule

After initiating anti‑VEGF therapy, most patients return every 4‑8 weeks for monitoring. Adherence to appointments is critical to maintain visual gains.

Prevention

While age cannot be altered, several evidence‑based measures lower the risk of developing wet AMD or slow its conversion from dry AMD:

• Quit smoking – seek nicotine‑replacement therapy or counseling.
• Adopt the AREDS2 supplement regimen – 500 mg vitamin C, 400 IU vitamin E, 10 mg lutein, 2 mg zeaxanthin, 80 mg zinc, and 2 mg copper daily (consult your eye doctor first).
• Maintain a healthy weight – BMI < 25 kg/m² is associated with lower AMD risk.
• Control blood pressure and cholesterol – follow DASH or Mediterranean diet, exercise regularly.
• Eat a retina‑friendly diet – 2–3 servings of leafy greens, fatty fish (salmon, mackerel) weekly, and nuts.
• Regular comprehensive eye exams – at least annually after age 50; earlier if you have risk factors.
• Limit prolonged exposure to intense blue light – use screen filters or glasses with blue‑light blocking lenses.

Complications

If left untreated or poorly controlled, wet AMD can lead to:

• Permanent central vision loss – irreversible scarring of the macula.
• Geographic atrophy – secondary degeneration of retinal pigment epithelium.
• Sub‑retinal fibrosis – scar tissue that further impairs vision.
• Psychological impact – depression, social isolation, reduced quality of life.
• Increased risk of falls – due to reduced visual acuity and depth perception.

When to Seek Emergency Care

Key Take‑aways

• Exudative (wet) AMD accounts for most severe vision loss from AMD but is treatable.
• Early detection via regular eye exams and self‑monitoring (Amsler grid) is crucial.
• Anti‑VEGF injections are the gold‑standard therapy and can improve vision in many patients.
• Lifestyle modifications—smoking cessation, healthy diet, blood‑pressure control—lower risk and support treatment outcomes.
• Never ignore sudden visual changes; seek urgent care to preserve sight.

For personalized advice, schedule an appointment with a retinal specialist. Trusted sources for further reading include the Mayo Clinic, CDC, NIH, WHO, and the Cleveland Clinic.

```